STOCK TITAN

10x Genomics, Inc. - TXG STOCK NEWS

Welcome to our dedicated page for 10x Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10x Genomics stock.

10x Genomics, Inc. (Nasdaq: TXG) is a leading life science technology company based in Pleasanton, California. The company specializes in creating innovative solutions for single cell and spatial biology research, providing researchers with the tools necessary to advance human health by deepening the understanding of complex biological systems.

10x Genomics' product portfolio includes cutting-edge instruments, consumables, and software designed for high-resolution, large-scale analysis of biological systems. Among its notable products are the Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software. The bulk of the company's revenue is generated from the sale of consumables, which are crucial for ongoing research and experimental workflows.

Recently, 10x Genomics launched the GEM-X technology, a significant upgrade to its existing single cell technology. The GEM-X platform offers enhanced performance and reliability, enabling more comprehensive single cell analysis. The company has also introduced the Xenium product line, including the Xenium multi-modal cell segmentation kit and an immuno-oncology gene panel, which expands their single cell spatial analysis capabilities.

Financially, 10x Genomics has demonstrated growth, with 2023 revenue reaching $618.7 million, an increase from the previous year. Although the company reported a net loss for the same period, the launch of new products like the Visium HD Spatial Gene Expression assay and the continued development of the GEM-X technology are expected to drive future growth and adoption among researchers worldwide.

10x Genomics collaborates closely with academic and translational researchers, as well as biopharmaceutical companies, to fuel discoveries in fields such as oncology, immunology, and neuroscience. Their integrated solutions enable scientists to study biological systems at a resolution and scale that aligns with the complexity of biology, making significant contributions to the understanding of health and disease.

To stay up-to-date with 10x Genomics' latest developments, visit their official website at 10xgenomics.com, or follow them on LinkedIn and X (Twitter).

Rhea-AI Summary
10x Genomics, Inc. (TXG) launches Visium HD Spatial Gene Expression product, enabling whole transcriptome spatial discovery at single cell–scale resolution. The product offers comprehensive characterization of FFPE tissue samples, combining transcriptome spatial discovery with histological insights. Visium HD provides best-in-class sequencing-based spatial transcriptomics data, FFPE compatibility, enhanced histology, and easy-to-use analysis and visualization tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Summary
10x Genomics, Inc. announces the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel. The company aims to enhance single cell spatial analysis with advanced AI algorithms and diverse stains, catering to researchers' needs for accurate cell segmentation and in-depth tumor microenvironment analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
-
Rhea-AI Summary
10x Genomics, Inc. introduces GEM-X technology architecture, enhancing single cell analysis with improved sensitivity, scalability, cost-efficiency, and data quality. The new products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, offer superior performance and workflow advantages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
Rhea-AI Summary
10x Genomics, Inc. (TXG) will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference. The event will be live-streamed on their website, with a replay option available for 45 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
Rhea-AI Summary
10x Genomics (TXG) reports Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over 2022. The company launched new products, increased instruments sold, and provided a positive outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) has announced the launch of GEM-X, the next generation of the company's leading single cell technology, offering higher performance at larger scale and lower cost. The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune Profiling 5'v3, with expected shipping in Q1. GEM-X offers substantial performance advantages, including increased sensitivity, scalability, cost-effectiveness, enhanced data quality, maximum sample recovery, and improved assay robustness, setting a new standard for single cell analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) has announced a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting. The new products aim to deliver higher performance, improve ease of use, and enable researchers to measure more biology. These include Visium HD for spatial discovery, Xenium In Situ platform for in situ analysis, and new capabilities for its Chromium Flex assay for single cell workflows. The company will also share new data and development directions across its three platforms at a workshop during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
Rhea-AI Summary
10x Genomics, Inc. (TXG) will release its financial results for Q4 and full year 2023 on February 15, 2024. The company will host a conference call and live webcast to discuss the results, business developments, and outlook. The webcast will be accessible on the company's website and archived for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences earnings
-
Rhea-AI Summary
10x Genomics, a leader in single cell and spatial biology, announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023. Revenue for the fourth quarter was approximately $184.0 million, with 18% growth over the corresponding prior year period. Full year revenue was approximately $618.7 million, representing 20% growth over the prior year. Instruments revenue saw significant growth, with approximately $123.5 million for the full year. The company also increased cumulative instruments sold to more than 5,900 as of the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences

FAQ

What is the current stock price of 10x Genomics (TXG)?

The current stock price of 10x Genomics (TXG) is $13.32 as of November 20, 2024.

What is the market cap of 10x Genomics (TXG)?

The market cap of 10x Genomics (TXG) is approximately 1.6B.

What does 10x Genomics, Inc. specialize in?

10x Genomics specializes in creating innovative solutions for single cell and spatial biology research, providing tools for high-resolution, large-scale analysis of biological systems.

What are some of the key products of 10x Genomics?

Key products include the Chromium Controller, Reagent Kits, 10x Compatible Products, Informatics Software, and the recently launched GEM-X and Xenium platforms.

What recent technological advancements has 10x Genomics introduced?

10x Genomics recently launched the GEM-X technology, a significant upgrade for single cell analysis, and the Visium HD Spatial Gene Expression assay for high-resolution spatial discovery research.

How has 10x Genomics performed financially in recent years?

In 2023, 10x Genomics reported a revenue of $618.7 million, reflecting a year-over-year increase. The company's continued innovation and product development are expected to drive future growth.

Who are the primary users of 10x Genomics' products?

10x Genomics' products are used by academic and translational researchers as well as biopharmaceutical companies to advance research in fields such as oncology, immunology, and neuroscience.

What is the significance of GEM-X technology?

GEM-X technology offers improved performance and reliability for single cell analysis, enabling more comprehensive research and better understanding of biological complexities.

Where can I find the latest news about 10x Genomics?

For the latest news and updates, visit 10x Genomics' official website at https://www.10xgenomics.com or follow them on LinkedIn and X (Twitter).

What is the focus of 10x Genomics' recent product launches?

Recent product launches focus on enhancing single cell and spatial biology research capabilities, including new assays and technology platforms like GEM-X and Visium HD.

What is the impact of 10x Genomics' products on scientific research?

10x Genomics' products enable high-resolution, large-scale analysis of biological systems, driving breakthroughs and transforming our understanding of health and disease.

How does 10x Genomics contribute to the field of biology?

10x Genomics provides tools that allow researchers to study biological systems at a resolution and scale that matches their complexity, facilitating significant scientific discoveries.

10x Genomics, Inc.

Nasdaq:TXG

TXG Rankings

TXG Stock Data

1.62B
103.97M
2.17%
94.44%
6.28%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
PLEASANTON